Navigation Links
Anti-psychotic medications offer new hope in the battle against glioblastoma
Date:3/7/2014

Researchers at the University of California, San Diego School of Medicine have discovered that FDA-approved anti-psychotic drugs possess tumor-killing activity against the most aggressive form of primary brain cancer, glioblastoma. The finding was published in this week's online edition of Oncotarget.

The team of scientists, led by principal investigator, Clark C. Chen, MD, PhD, vice-chairman, UC San Diego, School of Medicine, division of neurosurgery, used a technology platform called shRNA to test how each gene in the human genome contributed to glioblastoma growth. The discovery that led to the shRNA technology won the Nobel Prize in Physiology/Medicine in 2006.

"ShRNAs are invaluable tools in the study of what genes do. They function like molecular erasers," said Chen. "We can design these 'erasers' against every gene in the human genome. These shRNAs can then be packaged into viruses and introduced into cancer cells. If a gene is required for glioblastoma growth and the shRNA erases the function of that gene, then the cancer cell will either stop growing or die."

Chen said that one surprising finding is that many genes required for glioblastoma growth are also required for dopamine receptor function. Dopamine is a small molecule that is released by nerve cells and binds to the dopamine receptor in surrounding nerve cells, enabling cell communication.

Abnormal dopamine regulation is associated with Parkinson's disease, schizophrenia, and Attention Deficit Hyperactivity Disorder. Because of the importance of dopamine in these diseases, drugs have been developed to neutralize the effect of dopamine, called dopamine antagonists.

Following clues unveiled by their shRNA study, Chen and his team tested the effects of dopamine antagonists against glioblastoma and found that these drugs exert significant anti-tumor effects both in cultured cells and mouse models. These effects are synergistic when combined with other anti-glioblastoma drugs in terms of halting tumor growth.

"The anti-glioblastoma effects of these drugs are completely unexpected and were only uncovered because we carried out an unbiased genetic screen," said Chen.

"On the clinical front, the finding is important for two reasons," said Bob Carter, MD, PhD, chairman of UC San Diego, School of Medicine, division of neurosurgery. "First, these drugs are already FDA-cleared for human use in the treatment of other diseases, so it is possible these drugs may be re-purposed for glioblastoma treatment, thereby bypassing years of pre-clinical testing. Second, these drugs have been shown to cross the blood-brain barrier, a barrier that prevents more than 90 percent of drugs from entry into the brain."

Chen is now working with the UC San Diego Moores Cancer Center Neuro-Oncology team to translate his findings into a clinical trial.


'/>"/>
Contact: Jackie Carr
jcarr@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert  

Related medicine news :

1. New Risperdal Lawsuit Filed in Pennsylvania Litigation; Alleges Male Breast Growth Injuries Caused by Anti-Psychotic Medication, Bernstein Liebhard LLP Reports
2. Blood pressure medications given right after stroke not beneficial, study finds
3. MIT robot may accelerate trials for stroke medications
4. Fresno California's Hear for Life Hearing Aid Centers Publishes Warnings about Medications that Lead to Hearing Loss
5. Audiologists at American Hearing & Balance in Marina del Rey CA Educate Consumers About Everyday Medications That Cause Hearing Loss
6. Bernstein Liebhard LLP Launches New GranuFlo Lawsuit Website for Individuals Allegedly Injured by Recalled Dialysis Medications
7. Effect of reducing blood pressure with medications immediately following ischemic stroke
8. Watchful Waiting Can Do the Job of BPH Medications For Some Men, From the November 2013 Harvard Men's Health Watch
9. Racial difference in blood clotting warrants a closer look at heart attack medications
10. Mothers immunosuppressive medications not likely to put fetus at risk
11. Pain Management Therapeutics Market to 2019 - Impact of Patent Expiries Offset by Demand for Neuropathic and Rheumatoid Pain Medications and Strong Pipeline
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Anti-psychotic medications offer new hope in the battle against glioblastoma
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... ... conditions and Make-A-Wish grants the most heartfelt wishes of these children. The ... of medical treatment. President and CEO of Make-A-Wish Mississippi, Brent Wilson said, ...
(Date:5/5/2016)... ... ... Long Island’s fastest growing comprehensive eye care provider, North Shore Eye ... Valkenburg, MD as part of their ongoing effort to increase ophthalmic coverage in their ... of North Shore Eye Care. , “We are extremely proud to welcome ...
(Date:5/5/2016)... ... ... TIME for Kids and The ZAC Foundation – a national leader in drowning ... million children with important water safety messages before summer break begins. , ... in children one to 6 years of age. TIME for Kids and The ...
(Date:5/5/2016)... ... , ... In honor of National Nurses Week 2016, Aya Healthcare , ... to thank a nurse who's made a difference in their life. From Friday, May ... Cross of San Diego/Imperial Counties (up to $10,000) every time someone tells them via ...
(Date:5/5/2016)... ... ... Lung Institute will celebrate its three-year anniversary on May 14 by giving away a ... of May. To date, the Lung Institute has treated over 2,000 people at their five ... to the success of this treatment and to the patients who refuse to give up,” ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... 2016 Research and ... Thalassaemia Market and Competitive Landscape Highlights - ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... Competitive Landscape Highlights - 2016, provides comprehensive ... Thalassaemia market valuations and forecast, Thalassaemia products ...
(Date:5/4/2016)... May 4, 2016 According to ... entitled "Brain Computer Interface Market - Global Industry Analysis, Size, ... brain computer interface (BCI) market  is expected to reach ... is estimated to expand at a CAGR of 14.9 ... A BCI device provides collaboration between the ...
(Date:5/4/2016)... -- According to market research "Global Computed Tomography ... 2022 - Industry Insights by Slice Type (High, Mid and ... P&S Market Research, the global computed tomography market ... expected to grow at a CAGR of 5.0% during 2016-2022. ... expected to witness the faster growth, CAGR of 5.3%, during ...
Breaking Medicine Technology: